Future Medicinal Chemistry
Future Medicinal Chemistry is a peer-reviewed medical journal covering all aspects of medicinal chemistry, including drug discovery, pharmacology, in silico drug design, structural characterization techniques, ADME-Tox investigations, and science policy, economic and intellectual property issues. It was established in 2009 and is published by Future Science. The editors-in-chief are Iwao Ojima (The State University of New York at Stony Brook) and Jonathan Baell (Monash University).
 | |
| Discipline | Medical chemistry |
|---|---|
| Language | English |
| Publication details | |
| History | 2009–present |
| Publisher | Future Medicine Ltd |
| Frequency | 18/year |
| 3.969 (2017) | |
| Standard abbreviations | |
| ISO 4 | Future Med. Chem. |
| Indexing | |
| CODEN | FMCUA7 |
| ISSN | 1756-8919 (print) 1756-8927 (web) |
| OCLC no. | 762952421 |
| Links | |
Abstracting and indexing
The journal is abstracted and indexed by BIOSIS Previews, Chemical Abstracts, Chemistry Citation Index, Embase/Excerpta Medica, Index Medicus/MEDLINE/PubMed, Science Citation Index Expanded, and Scopus. According to the Journal Citation Reports, the journal has a 2016 impact factor of 3.556, ranking it 11th out of 60 journals in the category "Chemistry, Medicinal".[1]
References
- "Journals Ranked by Impact: Chemistry, Medicinal". 2016 Journal Citation Reports. Web of Science (Science ed.). Thomson Reuters. 2017.